Regorafenib.png

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had 2 US approvals for advanced cancers.

Product Description:
1) Product Name:  Supply regorafenib/(BAY 73-4506) CAS:755037-03-7
2) Specification: 99%
3) Testing Method: HPLC
4) Appearance: White to off-white powder
Specifications
Items
Specifications
Results
Appearance
White to whitish crystal powder
Conforms
Loss on drying
NMT 0.5%
0.33%
Residue on ignition
NMT 0.1%
Conforms
Heavy metal
NMT 20ppm
Conforms
Assay (HPLC)
NLT 99.5%
99.77%
Related substances
NMT 0.5%
0.23%
Single impurity
NMT 0.1%
0.07%
Conclusion: Complies to the Enterprise standard
Packaging & Shipping:
25kg carton drum (32cm*58cm)or 1kg foil bag (10cm*15cm) or by request of clients
Transit could be DHL,UPS,TNT,EMS,Fedex,and so on.
For mass orders, it will be delivered by air or sea.
Depending on your location, please allow 1-5 business days for your order to arrive.
For small order, please expect 3-7 days by UPS DHL EMS.
For mass order, please allow 5-8 days by Air, 15-30 days by Sea.

my contact infomation is:
Whatsapp: 008615032102186
Email: bettyapi1989@163.com

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body

Advertisements